J&J's Reaction to Merck / SGP Likely to Come Soon

One issue in the Merck (MRK)/Schering Plough (SGP) deal that's come up since it was announced is Johnson & Johnson's (JNJ) role in it. They have a deal on Remicade and its follow-up golimumab, which provides significant revenue to S-P (who have the non-US rights). J&J is no doubt weighing their options Tuesday, because Merck and Schering-Plough structured their deal, by all appearances, specifically to avoid triggering some provisions that would make these rights revert to J&J.

Over at the S-P watchdog site Shearlings Got Plowed, we find this, referring to this partnership agreement which you can find at the SEC. Scrolling down to section 8.2, one finds (emphasis added):

(c) Change in Control. If either party is acquired by a third party or otherwise comes under Control (as defined in Section 1.4 above) of a third party, it will promptly notify the other party not subject to such change of control. The party not subject to such change of control will have the right, however not later than thirty (30) days from such notification, to notify in writing the party subject to the change of Control of the termination of the Agreement taking effect immediately. As used herein "Change of Control" shall mean (i) any merger, reorganization, consolidation or combination in which a party to this Agreement is not the surviving corporation; or (ii) any "person" (within the meaning of Section 13(d) and Section 14(d)(2) of the Securities Exchange Act of 1934), excluding a party's Affiliates, is or becomes the beneficial owner, directly or indirectly, of securities of the party representing more than fifty percent (50%) of either [A] the then-outstanding shares of common stock of the party or [B] the combined voting power of the party's then-outstanding voting securities; or (iii) if individuals who as of the Effective Date constitute the Board of Directors of the party (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board of Directors of the party; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the party's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board; or (iv) approval by the shareholders of a party of a complete liquidation or the complete dissolution of such party.

That's why the deal is, on paper, Schering-Plough acquiring Merck (of all things). S-P will be the "surviving corporation", you see, so J&J can just go away and keep splitting all that anti-TNF antibody revenue. Somehow I don't think that this is going to go that smoothly. Like "Condor" over at the Shearlings site, I don't see how that language about the board of directors can apply to the new board of the merged company, since Merck was clearly not a party to this agreement. It has to apply, I'd think, to the current Schering-Plough board, which will cease to exist in its present form. No, we're surely going to see some response from J&J, and very soon. They won't walk away from this one.

Comments

[Turnipseed:]

Take your touting elsewhere.


On Mar 10 08:49 PM zhybrids wrote:

> Bulls, flow $ into the Stem Cell Sector.
>
> The highly speculative stem cell sector includes small niche players
> like (seekingalpha.com/symbo...) Multicell technologies,
> which has partnered up with the likes of (seekingalpha.com/symbo...)
> corning , (seekingalpha.com/symbo...) Pfizer and (seekingalpha.com/symbo...)
> Bristol Meyers Squibb .
>
> Penny Stock Biotechnology / Are Stem Cell Companies the target for
> future acquisitions by big Pharma?
>
> Stem cell companies could be the next Bio . Com plays.
>
> 1 smaller unknown player , among the likes of Geron (seekingalpha.com/symbo...)
> is ATHX
>
> Obama signs executive order to remove the ban on federal funding
> for embryonic stem cells, today at 11:45 am.
>
> ATHX Is an undervalued Stem Cell Co. and the
> Insiders have been Buying!
>
> ATHX Trades at like 30 Cents on the $1.00 Just on Cash Alone. ZERO
> DEBT /and a Book Value of $1.88 , $1.78 in Cash per Share.
>
> The market is not pricing stocks correctly.
>
> ATHX .. In addition to its cash has built a Stem cell Pipeline ,
> with their multistem application.....
>
> Trading at .55 Cents. Does this make any sense..
>
>
> Its like buying a $1.00 Bill for .30 Cents , as this is approximately
> 30% of their cash value.........
>
>
> Anyone else have a stock trading at Below Cash and 0 Debt... Especially
> in the Stem Cell Sector ???
>
> Commments welcomed.
>
> Balance Sheet
> Total Cash (mrq): 33.47M
> Total Cash Per Share (mrq): 1.768
> Total Debt (mrq): 0
> Total Debt/Equity (mrq): N/A
> Current Ratio (mrq): 11.722
> Book Value Per Share (mrq): 1.884
>
> Share Statistics
> Average Volume (3 month)3: 157,118
> Average Volume (10 day)3: 87,912.5
> Shares Outstanding5: 18.93M
> Float: 12.71M
> % Held by Insiders1: 23.09%
> % Held by Institutions1: 29.10%
>
> Please Add ATHX Athersys Inc. to you watch list and stem cell stock
> list.
>
> Today's price range was .56 - .78 cents
> on 150K Volume. When volume picks up to 300K Plus , I believe a move
> over $1.00 may occur, as it had been as high as $4.49 in March of
> 2008 and $1.29 just a couple of weeks ago.
>
> This company (seekingalpha.com/symbo...) is traded on the
> Nasdaq.

Mar 11 06:01 PM